Literature DB >> 33743830

Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis.

Seonpyo Jang1,2, Woo Cheol Shin2, Min Ku Song3, Hyuk-Soo Han1,2, Myung Chul Lee1,2, Du Hyun Ro4,5.   

Abstract

PURPOSE: Even today, total knee arthroplasty (TKA) is associated with venous thromboembolism (VTE). The purpose of our study is to report the incidence of postoperative VTE and to compare the efficacy of commonly used orally administered antithrombotic agents.
MATERIALS AND METHODS: Seven hundred ad ninety-nine patients who underwent primary TKA were retrospectively reviewed. The patients were prescribed one of three antithrombotic agents: aspirin (n = 168), rivaroxaban (n = 117), or apixaban (n = 514). Before surgery, patient demographics and risk factors were matched via propensity scoring. After surgery, all three groups took the agent for 7 days and underwent ultrasonography to check for VTE.
RESULTS: The overall incidence of postoperative VTE was 15.4% (123/799). Only one patient developed symptomatic VTE. Female sex and staged bilateral TKA were risk factors for postoperative VTE. The postoperative VTE rates in the aspirin, rivaroxaban, and apixaban groups were 16.2%, 6.0%, and 17.1%, respectively, significantly lower in the rivaroxaban group (p <  0.02). The majority of VTEs in all three groups were calf-vein thromboses.
CONCLUSIONS: All agents showed enough efficacy as antithrombotic agents. Considering that aspirin is inexpensive, aspirin is a cost-effective option for preventing postoperative VTE.

Entities:  

Keywords:  Antithrombotic agent; Apixaban; Aspirin; Rivaroxaban; Total knee arthroplasty; Venous thromboembolism

Year:  2021        PMID: 33743830      PMCID: PMC7981904          DOI: 10.1186/s43019-021-00093-4

Source DB:  PubMed          Journal:  Knee Surg Relat Res        ISSN: 2234-0726


  30 in total

1.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  An imaging approach to deep vein thrombosis and the lower extremity thrombosis classification.

Authors:  C W K P Arnoldussen; C H A Wittens
Journal:  Phlebology       Date:  2012-03       Impact factor: 1.740

3.  A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Authors:  Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Eva Muehlhofer; Christoph Dierig; Frank Misselwitz; Peter Kälebo
Journal:  Circulation       Date:  2006-11-20       Impact factor: 29.690

4.  Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.

Authors:  Steven Kurtz; Kevin Ong; Edmund Lau; Fionna Mowat; Michael Halpern
Journal:  J Bone Joint Surg Am       Date:  2007-04       Impact factor: 5.284

5.  Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.

Authors:  Carlos Alves; Francisco Batel-Marques; Ana Filipa Macedo
Journal:  J Cardiovasc Pharmacol Ther       Date:  2011-12-01       Impact factor: 2.457

6.  Calf sonography for detecting deep venous thrombosis in symptomatic patients: experience and review of the literature.

Authors:  R H Gottlieb; J Widjaja; L Tian; D J Rubens; S L Voci
Journal:  J Clin Ultrasound       Date:  1999-10       Impact factor: 0.910

7.  Incidence and natural history of deep-vein thrombosis after total knee arthroplasty. A prospective, randomised study.

Authors:  Young-Hoo Kim; J S Kim
Journal:  J Bone Joint Surg Br       Date:  2002-05

8.  Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

Authors:  G E Raskob; A S Gallus; G F Pineo; D Chen; L-M Ramirez; R T Wright; M R Lassen
Journal:  J Bone Joint Surg Br       Date:  2012-02

Review 9.  Long-term outcomes after deep venous thrombosis of the lower extremities.

Authors:  P Prandoni; A W Lensing; M R Prins
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

10.  The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study.

Authors:  M Mushfiqur Rahman; Jacek A Kopec; Jolanda Cibere; Charlie H Goldsmith; Aslam H Anis
Journal:  BMJ Open       Date:  2013-05-14       Impact factor: 2.692

View more
  1 in total

1.  Low muscle mass is an independent risk factor for postoperative blood transfusion in total knee arthroplasty: a retrospective, propensity score-matched cohort study.

Authors:  Doohyun Hwang; Hyuk-Soo Han; Myung Chul Lee; Du Hyun Ro
Journal:  BMC Geriatr       Date:  2022-03-17       Impact factor: 3.921

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.